UAB 2078: A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin


Total Award Amount

  • 410254.00
  • Direct Costs

  • 315580.00
  • Sponsor Award Id

  • Contributor

  • Amitkumar Mehta M.D.   Principal Investigator  
  • Gaurav Goyal   Investigator  
  • Luciano Costa M.D., Ph.D.   Investigator  
  • Mayur Narkhede   Investigator  
  • Pankit Vachhani   Investigator